文章核心观点 - 公司Ginkgo Bioworks Holdings, Inc.被指在上市前的代理声明/注册声明中做出了虚假和误导性陈述 [1][2][5] - 这些虚假陈述包括: - 不准确地描述了影响报告收入和递延收入的关联方交易 [5] - 不准确地描述了公司提供的某些服务的价值 [5] - 将某些关联方错误地描述为独立方 [5] - 夸大了公司获得的非关联方收入 [5] - 这些违反了1933年证券法第11条和1934年证券交易法第14(a)条 [5] - 部分被告还被指违反了1934年证券交易法第10(b)条,有故意误导投资者的行为 [5] 根据目录分类总结 公司概况 - Ginkgo Bioworks Holdings, Inc.是一家生物技术公司,于2021年通过与SRNG公司合并上市 [2][5] 诉讼情况 - 该诉讼自2021年11月开始,原告指控公司在合并上市时做出了虚假和误导性陈述 [5] - 公司否认了这些指控,但为了解决该诉讼,同意支付1775万美元的和解金 [5] 和解方案 - 法院已初步批准了该和解方案 [1][2] - 和解方案将解决该诉讼及相关索赔 [5] - 如果投资者不退出,将受该判决的约束 [6][7] - 投资者如果想单独提起诉讼,可能面临时效期限的风险 [7] - 投资者如果不退出,可以就和解方案、分配方案或律师费用提出异议 [8]

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoi ...

The company is forging ahead with next-generation drug development solutions.Bioengineering specialist Ginkgo Bioworks Holdings (DNA 9.31%) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index.Two new products introducedGinkgo's news was conn ...

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industryModel API programmable interface now available for individual scientists and researchers to quickly test and advance workBOSTON, Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that wi ...

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research collaboration aimed at leveraging each company’s expertise to identify and develop novel small-molecule therapies against DNA-damage response (DDR) t ...

Could this beaten-down stock turn things around in the near future?If a stock is down more than 90% during the past year, you know there's something seriously wrong with the underlying business. Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (DNA 2.29%) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New York Stock Exchange. It has been in the midst of a stunning free fall as investors appear to have lost patience with the b ...

OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO:        ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. (“Ginkgo,” ...

The risks may resolve in a year or so but seizing the opportunities will take longer.When a stock you own is struggling to retain value, it pays to know what new problems might lie awaiting in its future. To have the conviction to retain your shares through a dip, you'll also need to appreciate the upcoming opportunities that might make your patience worth the while.Ginkgo Bioworks (DNA -5.64%) is facing a pair of big risks right now, but it also has a pair of big opportunities that could be enough to turn ...

The company is using artificial intelligence, and planning to help others use AI empowered by its data collection.Ginkgo Bioworks (DNA -5.64%) is a biotech that's going big on artificial intelligence (AI). Between its need to perform core workflows with high efficiency, and its generation of tons of biological and manufacturing data that demand analysis, Ginkgo will likely find AI becoming more important to it over time.That's especially true if it starts selling a key input that other biopharma companies n ...

Maravai LifeSciences Holdings, Inc. (MRVI) , through its subsidiaries Cygnus Technologies and TriLink BioTechnologies, has announced the launch of AccuRes Host Cell DNA Quantification Kits. This latest launch blends Cygnus’ advanced extraction techniques with TriLink’s cutting-edge CleanAmp dNTPs technology. The AccuRes kits offer increased sensitivity and specificity in detecting host cell DNA, ensuring the production of biotherapeutics that meet and exceed the most rigorous regulatory standards.Maravai Li ...